Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 15/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | FSHR | P23945 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068464 | 0.90 | LHCGR (0.69) | LHCGRTSHRFSHRMAPTMAPK1 | |
| SCHEMBL29997908 | 0.85 | LHCGR (0.71) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL4425902 | 0.84 | LHCGR (0.78) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL14285229 | 0.83 | LHCGR (0.73) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL5028843 | 0.83 | LHCGR (0.72) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL30068474 | 0.81 | LHCGR (0.68) | LHCGRTSHRFSHR | |
| SCHEMBL4425858 | 0.81 | LHCGR (0.71) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL4421168 | 0.81 | LHCGR (0.84) | LHCGRTSHRFSHRBRAF | |
| SCHEMBL4432570 | 0.80 | LHCGR (0.67) | LHCGRTSHRFSHR | |
| SCHEMBL4315364 | 0.80 | LHCGR (1.00) | LHCGRTSHRFSHRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351655-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | University of Georgia Research Foundation, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4351659-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | University of Georgia Research Foundation, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2022261191-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022261213-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022261186-A1 | NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20250288532-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4351655-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | University of Georgia Research Foundation, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351659-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | University of Georgia Research Foundation, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261213-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261191-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261186-A1 | NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288532-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | FSHR, GNRHR, AR | LHCGR 6/4885TSHR 271/4885FSHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.